Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity

The toxicity arising from generalised stimulation of T cells restricts applicability of CD137 agonists in cancer immune therapy. Here authors show that a bispecific antibody blocking PD-1 while activating CD137 efficiently restricts T cell activation to the tumour microenvironment, resulting in effi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yunqian Qiao, Yangmin Qiu, Jie Ding, Nana Luo, Hao Wang, Xiaomin Ling, Jiya Sun, Zhihai Wu, Yisen Wang, Yanpeng Liu, Feifei Guo, Ta Sun, Wanwan Shen, Min Zhang, Dongdong Wu, Bingliang Chen, Wei Xu, Xuan Wang
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/5a74607a784c4173b05f771b90d4abb5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:The toxicity arising from generalised stimulation of T cells restricts applicability of CD137 agonists in cancer immune therapy. Here authors show that a bispecific antibody blocking PD-1 while activating CD137 efficiently restricts T cell activation to the tumour microenvironment, resulting in efficient tumour control and reduced liver toxicity.

Ejemplares similares